Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Trial Details
- NCT ID
- NCT06995677
- Phase
- PHASE2
- Sponsor
- Tyra Biosciences, Inc
- Status
- RECRUITING
- Cancer Type
- Bladder Cancer
- Interventions
- TYRA-300 60mg
- TYRA-300 50mg
- TYRA-300 Dose TBD
- Locations (sample)
- Homewood, Alabama, United States|33.47177,-86.80082
- Little Rock, Arkansas, United States|34.74648,-92.28959
- Murrieta, California, United States|33.55391,-117.21392
- Rancho Mirage, California, United States|33.73974,-116.41279
- San Diego, California, United States|32.71571,-117.16472
Key Eligibility Criteria
- Participants age ≥18 at time of informed consent and willing and able to comply with all required study procedures
- Able to understand and given written informed consent
- Participants with histologically confirmed low-grade NMIBC within 8 weeks prior to C1D1 with prior diagnostic biopsy/TURBT to confirm stage and gra…
- Ta low grade
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Bladder Cancer Trials on Trialify →